Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial

Novo Nordisk’s GLP-1/amylin combo drug CagriSema was not as good as Eli Lilly’s marketed obesity shot Zepbound in a head-to-head study, the Danish company said Monday. Patients in the REDEFINE 4 ...